Elevated Monocyte to High-density Lipoprotein Ratio Is a Risk Factor for New-onset Atrial Fibrillation after Off-pump Coronary Revascularization

Atrial fibrillation (AF) is a common complication of coronary revascularization. Currently, the mechanisms of postoperative AF are unclear. This study was aimed at investigating the risk factors for new-onset AF (NOAF) after coronary revascularization and exploring the early warning effects of clinical inflammatory markers. A retrospective analysis was conducted on 293 patients with unstable angina pectoris who underwent coronary artery revascularization in Beijing Chao-Yang Hospital, Capital Medical University, between April 2018 and June 2021, including 224 patients who underwent coronary artery bypass grafting and 69 patients who underwent one-step hybrid coronary revascularization. Baseline data, clinical data, blood indicators and AF episodes within 7 days after the surgery were collected. Participants were divided into two groups according to whether AF occurred, and the data were analyzed between groups. In addition, multivariate logistic regression was used to explore the independent risk factors for developing AF post coronary revascularization. Aging, a larger left atrial inferior-superior diameter, use of an intra-aortic balloon pump, a greater blood volume transfused during perioperative period and a higher monocyte to high-density lipoprotein ratios on postoperative day 1 were independent risk factors for NOAF after coronary artery surgery

Thyroid function and associated mood changes after COVID-19 vaccines in patients with Hashimoto thyroiditis

ContextSevere acute respiratory syndrome-coronavirus 2 (COVID-19) vaccines may incur changes in thyroid functions followed by mood changes, and patients with Hashimoto thyroiditis (HT) were suggested to bear a higher risk.ObjectivesWe primarily aim to find whether COVID-19 vaccination could induce potential subsequent thyroid function and mood changes. The secondary aim was to find inflammatory biomarkers associated with risk.MethodsThe retrospective, multi-center study recruited patients with HT receiving COVID-19–inactivated vaccines. C-reactive proteins (CRPs), thyroid-stimulating hormones (TSHs), and mood changes were studied before and after vaccination during a follow-up of a 6-month period. Independent association was investigated between incidence of mood state, thyroid functions, and inflammatory markers. Propensity score–matched comparisons between the vaccine and control groups were carried out to investigate the difference.ResultsFinal analysis included 2,765 patients with HT in the vaccine group and 1,288 patients in the control group. In the matched analysis, TSH increase and mood change incidence were both significantly higher in the vaccine group (11.9% versus 6.1% for TSH increase and 12.7% versus 8.4% for mood change incidence). An increase in CRP was associated with mood change (p< 0.01 by the Kaplan–Meier method) and severity (r = 0.75) after vaccination. Baseline CRP, TSH, and antibodies of thyroid peroxidase (anti-TPO) were found to predict incidence of mood changes.ConclusionCOVID-19 vaccination seemed to induce increased levels and incidence of TSH surge followed by mood changes in patients with HT. Higher levels of pre-vaccine serum TSH, CRP, and anti-TPO values were associated with higher incidence in the early post-vaccine phase

Identifying the role of transient receptor potential channels (TRPs) in kidney renal clear cell carcinoma and their potential therapeutic significances using genomic and transcriptome analyses

Abstract Kidney renal clear cell carcinoma (KIRC) is among the major causes of cancer-caused mortality around the world. Transient receptor potential channels (TRPs), due to their role in various human diseases, might become potential drug targets in cancer. The mRNA expression, copy number variation, single-nucleotide variation, prognostic values, drug sensitivity, and pathway regulation of TRPs were studied across cancer types. The ArrayExpress and The Cancer Genome Atlas (TCGA) databases were used to retrieve KIRC samples. Simultaneously, training, internal, and external cohorts were grouped. In KIRC, a prognostic signature with superior survival prediction in contrast with other well-established signatures was created after a stepwise screening of optimized genes linked to TRPs using univariate Cox, weighted gene co-expression network analysis, multivariate Cox, and least absolute shrinkage and selection operator regression analyses. Subsequent to the determination of risk levels, the variations in the expression of immune checkpoint genes, tumor mutation burden, and immune subtypes and response between low-risk and high-risk subgroups were studied using a variety of bioinformatics algorithms, including ESTIMATE, XCELL, EPIC, CIBERSORT-ABS, CIBERSORT, MCPCOUNTER, TIMER, and QUANTISEQ. Gene set enrichment analysis helped in the identification of abnormal pathways across the low- and high-risk subgroups. Besides, high-risk KIRC patients might benefit from ABT888, AZD6244, AZD7762, Bosutinib, Camptothecin, CI1040, JNK inhibitor VIII, KU55933, Lenalidomide, Nilotinib, PLX4720, RO3306, Vinblastine, and ZM.447439; however, low-risk populations might benefit from Bicalutamide, FH535, and OSI906. Finally, calibration curves were used to validate the nomogram with a satisfactory predictive survival probability. In conclusion, this research provides useful insight that can aid and guide clinical practice and scientific research

TC-1 overexpression promotes cell proliferation in human non-small cell lung cancer that can be inhibited by PD173074.

Thyroid cancer-1 (TC-1), a natively disordered protein, is widely expressed in vertebrates and overexpressed in many kinds of tumors. However, its exact role and regulation mechanism in human non-small cell lung cancer (NSCLC) are still unclear. In the present study, we found that TC-1 is highly expressed in NSCLC and that its aberrant expression is strongly associated with NSCLC cell proliferation. Exogenous TC-1 overexpression promotes cell proliferation, accelerates the cell G1-to-S-phase transition, and reduces apoptosis in NSCLC. The knockdown of TC-1, however, inhibits NSCLC cell proliferation, cycle transition, and apoptosis resistance. Furthermore, we also demonstrated that PD173074, which functions as an inhibitor of the TC-1 in NSCLC, decreases the expression of TC-1 and inhibits TC-1 overexpression mediated cell proliferation in vitro and in vivo. Nevertheless, the inhibition function of PD173074 on NSCLC cell proliferation was eliminated in cells with TC-1 knockdown. These results suggest that PD173074 plays a significant role in TC-1 overexpression mediated NSCLC cell proliferation and may be a potential intervention target for the prevention of cell proliferation in NSCLC

Cognitive adverse events in patients with lung cancer treated with checkpoint inhibitor monotherapy: a propensity score-matched analysisResearch in context

Summary: Background: Cancer-related cognitive decline is a serious problem in long-term survival but no pivotal study has investigated whether checkpoint inhibitors (ICI) may be associated with cognitive adverse events. Methods: This propensity score-matched analysis recruited non-small cell lung cancer (NSCLC) patients prescribed with or without ICI monotherapy from three Chinese tertiary hospitals. Patients were excluded from study who developed brain metastasis or had disorders severely affecting cognitive abilities. Primary outcomes were changes in neuropsychological battery test (NBT) at baseline, 6- and 12-month sessions, and any NBT score changes that exceeded 3∗SD of baseline scores would be marked as objective cognitive adverse events (CoAE). Secondary endpoint was the 20-item Perceived Cognitive Impairment (PCI) sub-scale score change in Functional Assessment of Cancer Therapy-Cognitive Function questionnaire, administered at baseline, 3-, 6-, 9-, 12-, and 15-month follow-up session. Per-protocol ICI and control arms were matched with propensity scores that incorporated baseline variables to compare both NBT and PCI assessment results. Patients participating in PCI assessments were analysed in intention-to-treat analysis. Kaplan–Meier survival curves with log-rank tests were adopted to analyse incidence of perceived cognitive decline events (PCDE). Findings: Between March 12, 2020, and March 28, 2021, 908 participants were enrolled. Compared to control, 3 of 4 subtest of NBT scores in ICI arm showed significant cognitive decline in 6- and 12-month sessions, in which Trail Making Test score change (13.56 ± 11.73) reached threshold of cognitive deficit diagnosis in the 12-month session. In 1:1 matched 292 pairs from 908 patients, PCI score changes in ICI arms were −4.26 ± 8.54 (3rd month), −4.72 ± 11.83 (6th month), −6.16 ± 15.41 (9th month), −6.07 ± 15.71 (12th month), and −7.96 ± 13.97 (15th month). The scores were significantly lower than control arm in 3-, 6-, and 12-session follow-up. The result was validated after adjusting quality of life scores and in intention-to-treat analysis. Mean PCI change exceeded 1/2 SD of baseline PCI score (5.81) in 9-, 12-, and 15-month sessions in ICI arm, but not in control arm. PCDE incidence/prevalence was significantly higher in ICI arm (incidence 26.4% vs. 5.1%, and prevalence 16.2% vs. 1.7%). Immune-related adverse events related to incidence of PCDE after adjusting for baseline variables. Interpretation: ICI monotherapy seemed to relate to higher cognitive decline represented by score changes and incidence/prevalence rates. The decline deteriorated as treatment progressed, and immune-related adverse events seemed to be associated with higher cognitive adverse events incidence in the ICI treatment. Funding: The Fellowship of China Postdoctoral Science Foundation and National Natural Science Foundation of China Youth Science Fund Project

PD173074 inhibition of cell proliferation, cycle transition, and apoptosis resistance depends on the TC-1 expression level <i>in vivo</i>.

<p>Subcutaneous tumor model (n = 10). A549- pLenti-shRNA1 or A549 cells were implanted into the flank of nude mice. PD173074 or buffer alone was administered daily for 28 days. In addition, the mice received or did not receive two doses of 5 mg/kg cisplatin i.v. on days 1 and 15. (A, C) The tumor volumes were scored 28 days after the first administration of PD173074. (B, D) The animal survival was recorded as a Kaplan-Meier plot. The columns represent the average tumor volume. The bars show the SE. *indicates statistically significant changes (Student’s t test, P<0.05) between two groups. CIS, Cisplatin.</p

Relationship between TC-1 expression and clinicopathological characteristics in NSCLC tissues.

<p>Relationship between TC-1 expression and clinicopathological characteristics in NSCLC tissues.</p

Stable clones of NSCLC cells overexpressing or downregulating TC-1 were constructed successfully.

<p>qRT-PCR and western blotting showed that A549, SPC-A-1, and 95D cells express high levels of TC-1 mRNA and protein and that NCI-H520 cells express low levels of TC-1 mRNA and protein (A). The qRT-PCR and western blotting results shown in B and C, respectively, show that TC-1 mRNA and protein are significantly downregulated in A549-pLenti-shRNA1 cells and significantly upregulated in NCI-H520-pLenti-TC-1 cells compared with the controls. The columns represent the average of the relative mRNA quantity from at least three independent experiments. The bars show the SE. *indicates statistically significant changes (P<0.05) among five groups (A) or three groups (B, C).</p

PD173074 inhibits the expression of TC-1 in A549 and A549-pLenti-shRNA1 cells.

<p>The qRT-PCR and western blotting results showed that the expression level of TC-1 decreased with an increase in the concentration of PD173074 and levels out when the concentration of PD173074 reaches 1 µΜ in A549 (A) and A549-pLenti-shRNA1 (B) cells. The columns represent the average of the relative mRNA quantity from at least three independent experiments. The bars show the SE. *indicates statistically significant changes (P<0.05) among five groups.</p